Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Available 2Unknown 1Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Endocrine 1

Conditions

Neuroblastoma 13Pheochromocytoma 5Neuroendocrine Tumors 4Neoplasms 3Recurrence 2Paraganglioma 2Neoplasm Metastasis 2Ganglioneuroblastoma 1Disease 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrence × 3-Iodobenzylguanidine × Clear all
NCT01313936 2019-04-29

High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma

University of California, San Francisco

Phase 1 Completed
32 enrolled 8 charts
CNS

Neoplasms, Neuroblastoma, Recurrence

NCT01413503 2018-09-18

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

University of California, San Francisco

Phase 2 Completed
50 enrolled 7 charts
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡